Carson Lisa Cabott 4
4 · Phio Pharmaceuticals Corp. · Filed Feb 6, 2026
Research Summary
AI-generated summary of this filing
Phio Pharmaceuticals (PHIO) CFO Carson Lisa Cabott Receives 47,000 RSUs
What Happened
- Carson Lisa Cabott (CFO) received a grant of 47,000 restricted stock units (RSUs) on 2026-02-05. The reported acquisition price was $0.00 (typical for RSU awards); total reported value at grant was $0. These RSUs represent a compensation award, not an open-market purchase.
Key Details
- Transaction date: 2026-02-05; Form filed: 2026-02-06 (timely filing).
- Transaction type/code: Award/Grant (A); 47,000 shares acquired at $0.00.
- Vesting: Footnote F1 — these RSUs will vest on the first annual anniversary of the grant (approximately 2027-02-05).
- Holdings note: Footnote F2 indicates the filing’s reported holdings include shares underlying unvested RSUs.
- No immediate sale or cashless exercise reported; this is a compensation grant rather than a market trade.
Context
- RSU grants are common executive compensation and become actual shares only upon vesting; they do not by themselves signal a purchase intent. Retail investors should view this as part of compensation structure rather than an outright insider buy or sell.
Insider Transaction Report
Form 4
Carson Lisa Cabott
Chief Financial Officer
Transactions
- Award
Common Stock, $.0001 par value
[F1][F2]2026-02-05+47,000→ 94,000 total
Footnotes (2)
- [F1]Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant.
- [F2]Includes shares of common stock underlying unvested restricted stock units.
Signature
/s/ Lisa C. Carson|2026-02-06